Sudhir Srivastava | |
---|---|
Occupation | Scientist |
Sudhir Srivastava is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States NCI. [1] [2] Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of Hereditary non-polyposis colorectal cancer (HNPCC). [1]
Srivastava is an elected member of the American Joint Committee on Cancer (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium. [3] Srivastava is a founding member of HUPO, participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives. [4]
Sudhir Srivastava | |
---|---|
Occupation | Scientist |
Sudhir Srivastava is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States NCI. [1] [2] Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of Hereditary non-polyposis colorectal cancer (HNPCC). [1]
Srivastava is an elected member of the American Joint Committee on Cancer (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium. [3] Srivastava is a founding member of HUPO, participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives. [4]